Bivalirudin cardiopulmonary bypass

Author: niid

August undefined, 2024

WebFeb 1, 2004 · We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass … WebA total of 21 adult patients received bivalirudin with infusion rates ranging from 0.028 to 0.2 mg/kg/h with or without initial bolus doses. 10 This wide variability in dosing requirements was also observed in our present analysis with maintenance rates achieving target aPTT ranges of 0.04 to 0.26 mg/kg/h.

This Month in Anesthesiology Anesthesiology American Society …

WebFeb 1, 2024 · However, pharmacokinetic studies during cardiac surgery are only available for bivalirudin. 11,12 During surgery with … WebFeb 14, 2024 · Although intravenous anticoagulation for pediatric cardiac catheterization and cardiac surgery procedures requiring cardiopulmonary bypass (CPB) is almost exclusively accomplished with heparin, there are certain clinical situations in which alternative agents are either required, as with heparin-induced thrombocytopenia (HIT) or … h\\u0026m edition

Use of Bivalirudin as an Anticoagulant During Cardiopulmonary …

WebIn this comprehensive review, the authors highlight heparin-induced thrombocytopenia's risk factors, clinical presentation, pathophysiology, diagnostic principles, and treatment. The authors place special emphasis on the management of patients requiring procedures using cardiopulmonary bypass or interventions in the catheterization laboratory. WebJun 19, 2024 · On-pump:Initial bolus: 1 mg/kg, followed by continuous infusion 2.5 mg/kg/hour; 50 mg bolus added to priming solution of cardiopulmonary bypass (CPB) circuit. Additional boluses of 0.1 to 0.5 mg/kg may … WebMar 1, 2024 · The reported doses of bivalirudin in patients undergoing cardiac surgery with cardiopulmonary bypass circulation include bolus of 0.75 to 2.5 mg/kg, followed by a continuous infusion at the titrated rate of 1.75 to 2.5 mg/kg/h [7]. During extracorporeal circulation ACT measurement is used to assess proper bivalirudin dose and the desired … hoffmann jacobsen

Bivalirudin anticoagulation for cardiopulmonary bypass in a …

Bivalirudin in Patients with HIT or Clinically Suspected HIT.

WebHeparin is used to provide anticoagulation during cardiopulmonary bypass, but it has disadvantages including potential development of antiplatelet factor 4/heparin antibodies. A recommended alternative to heparin, bivalirudin, has its own disadvantages including the lack of a reversal agent. Dabigatran may be a better alternative in patients ... WebFeb 1, 2007 · Background. The coronary artery bypass grafting (CABG) heparin-induced thrombocytopenia thrombosis syndrome (HITTS) on- and off-pump safety and efficacy … hoffmann janz architectsWebBackground: The coronary artery bypass grafting (CABG) heparin-induced thrombocytopenia thrombosis syndrome (HITTS) on- and off-pump safety and efficacy … hoffmann jean-nicolas

"WebPopulation pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers " - Bivalirudin cardiopulmonary bypass

Bivalirudin cardiopulmonary bypass

Dose Estimation for Bivalirudin during Pediatric Cardiopulmonary Bypass ...

WebMar 11, 2004 · Drug: Angiomax (bivalirudin) 250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative … WebFeb 1, 2007 · Background. The coronary artery bypass grafting (CABG) heparin-induced thrombocytopenia thrombosis syndrome (HITTS) on- and off-pump safety and efficacy …

Did you know?

WebInfants with heparin-induced thrombocytopenia (HIT) represent a challenging and high-risk group of patients when they require cardiopulmonary bypass (CPB). Bivalirudin offers many potential pharmacologic advantages over other nonheparin anticoagulants for such patients. We describe our protocol for … Webwe used heparin for cardiopulmonary bypass (CPB) anticoagulation. The baseline celite ACT was 123 seconds and after a heparin dose of 42,000 U (600 U/kg) the celite ACT was 660 seconds. On CPB, in addition to 10,000 U of heparin in the pump FiguRe 1: Heparin concentration. FiguRe 2: Activated clotting time (ACT).

WebTY - JOUR T1 - Use of bivalirudin as an anticoagulant during cardiopulmonary bypass. AU - Veale,James J, AU - McCarthy,Harry M, AU - Palmer,George, AU - Dyke,Cornelius M, PY - 2005/12/15/pubmed PY - 2006/2/8/medline PY - 2005/12/15/entrez SP - 296 EP - 302 JF - The journal of extra-corporeal technology JO - J Extra Corpor Technol VL - 37 IS - 3 … WebMar 1, 2024 · After informed consent, 10 sequential patients presenting for elective cardiac surgery requiring cardiopulmonary bypass received bivalirudin anticoagulation in lieu …

WebApr 13, 2024 · Use of botulinum toxin A to reduce AF was assessed in the NOVA (NeurOtoxin for the PreVention of Post-Operative Atrial Fibrillation) study which randomised 323 patients undergoing cardiac (bypass and/or valve) surgery to epicardial botulinum toxin A (125 units or 250 units) versus placebo . Overall, botulinum 125 units or 250 units … WebBivalirudin anticoagulation for cardiopulmonary bypass in a patient with heparin-induced throm- bocytopenia (L'anticoagulation avec la bivalirudine pour la circulation extracorporelle chez un patient atteint de thrombocytopénie immunitaire à l'héparine (TIH))

WebHeparin-induced IgE-mediated hypersensitivity and anaphylactoid reactions, although rare, can pose a serious clinical problem for patients requiring cardiopulmonary bypass …

WebMay 9, 2012 · Owing to its pharmacological profile, bivalirudin is rapidly cleaved by proteolytic enzymes, and its half-life is about 25 minutes when the renal function is normal [].The use of bivalirudin for cardiopulmonary bypass (CPB) [] and ECMO [] is a feasible option.However, it is recommended that, during CPB, blood stagnation in the circuit be … h \u0026 m electric motorsWebBivalirudin is metabolized by intracellular proteolysis, with 20% excreted unchanged by the kidneys. Wolstencroft, Arnold and Anderson present a study using allometry to determine appropriate bivalirudin infusion rates for pediatric patients requiring bivalirudin for cardiopulmonary bypass (CPB) anticoagulation 1. h\u0026m erdem fashion showWebOct 1, 2005 · Bivalirudin plasma concentration during cardiopulmonary bypass Weight-based dosing of bivalirudin is possible because of predictable and reliable … h\u0026m drop off old clothesWebCurrently, bivalirudin in cardiac surgery with cardiopulmonary bypass has a limited clinical spectrum, likely because the still obvious advantages of its competitor, heparin, outweigh it in terms ... hoffman njWebHIT complicates the management of patients presenting for cardiac surgery, particularly those who need cardiopulmonary bypass (CPB) which requires a large dose of UFH. A portion of these patients will have significant thrombotic complications referred to as HITT (Heparin-induced thrombocytopenia with thrombosis). h\u0026m exam site availabilityWebResults awaiting publication from a trial of bivalirudin at our institution for cardiopulmonary bypass cases demonstrate equal or less chest tube drainage and blood utilization than standard heparin anticoagulation for cardiac surgery. Bivalirudin has a plasma half-life of 25 min , which is substantially shorter than argatroban, and a unique ... h\u0026m excavating pentictonWebThe hypothesis that dabigatran would provide sufficient anticoagulation for cardiopulmonary bypass was tested in a first-use, proof-of-concept study using a rabbit model of cardiopulmonary bypass that included a comparison group receiving heparin. The dabigatran loading dose and maintenance infusions were designed after first … h\u0026m eid collection